Riverain’s ClearRead chest AI goes enterprise: FDA-cleared lung and heart imaging reaches 2,500 hospitals via RapidAI
Riverain Technologies announced today that its FDA-cleared ClearRead Chest suite will be available through RapidAI’s Rapid Enterprise Platform, putting its lung and cardiac imaging AI in front of radiologists at more than 2,500 hospitals.
Riverain Technologies announced on October 7 that its FDA-cleared ClearRead Chest suite will be available through RapidAI's Rapid Enterprise Platform, bringing the company's cardiothoracic imaging AI into the clinical workflows radiologists already use. Per the announcement, ClearRead Chest becomes available to RapidAI's install base of more than 2,500 hospitals — a distribution deal that turns a standalone chest-imaging tool into enterprise-grade infrastructure.
The move is a case study in how clinical AI actually scales. Regulatory clearance gets you into the market; distribution through the platforms hospitals already run gets you onto the reading worklist. Riverain is betting that embedding ClearRead inside RapidAI's platform — rather than selling yet another separate system to overwhelmed radiology departments — is the faster path to adoption.
What ClearRead does
ClearRead Chest is a cardiothoracic AI suite built for chest CTs and X-rays. It helps radiologists detect, characterize and visualize pulmonary nodules, pneumothoraces and coronary artery calcification — three findings where catching a subtle change early changes the outcome, from lung cancer to cardiovascular disease. A signature piece of the technology is Riverain's patented vessel and bone suppression, which strips vascular and bony structures out of the image to give an unobstructed view of the lungs, so nodules and other pathology are easier to spot.
Per the companies, the suite delivers its accuracy gains and time savings inside radiologists' existing workflows — the point being less cognitive burden, not a new console to learn.
Inside the integration
ClearRead Chest is being integrated across the Rapid Enterprise Platform: RapidAI's Rapid Edge Cloud infrastructure, the Rapid Navigator Pro radiology workflow solution, RapidAI's mobile and web applications, and its AI governance capabilities. The combined setup is designed to work across PACS, EHR and reporting systems, so a health system can add Riverain's chest AI without stitching together separate systems.
That's the strategic core of the deal. Health systems are drowning in point AI tools, each with its own login, workflow and validation burden. Riverain gets to ride inside a platform already deployed in thousands of hospitals; RapidAI gets a clinically validated third-party AI for lung and cardiovascular disease that slots into its existing full-body imaging portfolio.
Why it matters
“ClearRead was developed to help radiologists see subtle chest findings more clearly and confidently within the workflows they already rely on every day,” said Riverain CEO Steve Worrell, framing the integration as a way to support earlier detection of lung cancer and cardiovascular disease while reducing the burden on radiologists facing heavier imaging workloads.
The context: radiology is the clinical specialty where AI has the clearest product-market fit — and the most fragmented adoption. Deals like this one, where a validated vendor plugs into a deployed enterprise platform, are how AI imaging moves from pilot studies to default infrastructure. Watch whether RapidAI's governance layer — the audit and oversight controls health systems actually need for regulated AI — becomes the differentiator as more third-party models join the platform.
Sources: press release via EIN Presswire; Cardiac Vascular News; Biz RapidX.